PharmiWeb1h
Phase III study shows Xolair may be more effective…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored phase III OUtMATCH study, which provide further ...
The Mail5h
The end of an era for pharmaceutical giant
This summer is likely to be an emotional time for many in Ulverston.
Pharmabiz6h
EMA committee recommends marketing approval for Novartis oral Fabhalta to treat adults living with C3 glomerulopathy
EMA committee recommends marketing approval for Novartis oral Fabhalta to treat adults living with C3 glomerulopathy: Basel Monday, March 3, 2025, 10:00 Hrs [IST] Novartis announc ...
capitalbrief6h
Small-cap ASX biotech Avecho strikes Sandoz deal for CBD insomnia treatment
An Australian biotech minnow wants to become the first company globally to register an over-the-counter cannabidiol product ...
manilatimes12h
Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies
Additionally, preliminary results from Stage 3 of the OUtMATCH study provide early data on introducing allergenic foods into ...